KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Equity Average (2016 - 2025)

Historic Equity Average for Fulgent Genetics (FLGT) over the last 10 years, with Q3 2025 value amounting to $1.1 billion.

  • Fulgent Genetics' Equity Average fell 93.99% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 93.99%. This contributed to the annual value of $1.1 billion for FY2024, which is 567.95% down from last year.
  • Fulgent Genetics' Equity Average amounted to $1.1 billion in Q3 2025, which was down 93.99% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Fulgent Genetics' Equity Average registered a high of $1.3 billion during Q2 2022, and its lowest value of $685.5 million during Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $1.1 billion (2024), whereas its average is $1.1 billion.
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 92264.7% in 2021, then tumbled by 1092.91% in 2024.
  • Quarter analysis of 5 years shows Fulgent Genetics' Equity Average stood at $1.1 billion in 2021, then grew by 15.42% to $1.3 billion in 2022, then fell by 6.01% to $1.2 billion in 2023, then fell by 5.41% to $1.1 billion in 2024, then decreased by 1.13% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $1.1 billion for Q2 2025, and $1.1 billion during Q1 2025.